PEN (Penumbra) Risk Assessment


PEN Penumbra Inc PEN
89 GF Score
Price $317.28
GF Value $332.37
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Penumbra is: Low Risk: Strong fundamentals, worth long-term holding.

Penumbra  (NYSE:PEN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Penumbra Risk Assessment Related Terms

PEN vs GMED, PODD, BRKR: Risk Assessment Comparison

For the Medical Devices subindustry, Penumbra's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Penumbra Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Penumbra's Risk Assessment falls into.


PEN
89GF Score
Penumbra Inc PEN
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Penumbra (PEN) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of $317.28 is trading 4.5% below its estimated GF Value™ of $332.37. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for PEN:

  • Risk Assessment:
  • GF Value™: $332.37 vs. price of $317.28 (4.5% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Penumbra Business Description

Other Exchanges 0P8:Germany
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score

Get the complete analysis for PEN

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$317.28
Price
$332.37
GF Value